The FDA rapped contract manufacturer Formulation Technology for not validating laboratory analysis methods and not restricting access to pivotal data. The contractor received a Form 483 with 11 observations after a two-month inspection of its Oakdale, Calif., facility earlier this year.
Drug GMP Report